• June 16-19, 2025
  • Boston Convention & Exhibition Center

Caliway Biopharmaceuticals Co.,Ltd.

Loading

Caliway Biopharmaceuticals Co.,Ltd.

Wednesday, June 05, 2024
Company Presentation
Dermatology
Company Presentation Theater 2
Caliway focuses on breakthrough medical aesthetics and inflammatory medicine of novel small molecule therapeutics with unmet medical needs. Our leading candidate, CBL-514, is a first-in-class new drug that can trigger adipocyte apoptosis at the injection site and effectively reduce subcutaneous fat without causing tissue necrosis or prominent side effects. The results of the CBL514 clinical trial(currently PhIIb) could potentially compete in the more than $100 billion prescription fat reduction market or serve as a complementary treatment for medications like GLP-1. For the same molecule, under a different formulation, CBL-514 is also being developed as a Rare Disorder medication with the current indication for Dercum’s disease and has received Fast Track Designation and Orphanage Drug Designation from FDA(USA) in February 2024.
Caliway Biopharmaceuticals Co.,Ltd.
Company Website: https://www.caliway.com.tw/en/
Lead Product in Development: CBL-514
Number Of Unlicensed Products (For Which You Are Seeking Partners): 6

Exchange

Caliway at Taipei Exchange 6919

Ticker

Caliway at Taipei Exchange 6919

Company HQ City

New Taipei City 221

Company HQ State

Taiwan (R.O.C.)

Company HQ Country

Taiwan

CEO/Top Company Official

Vivian Liang

Development Phase of Primary Product

Phase II
Speakers
April Yuan, MBA
VP, Business Development & Public Affairs
Caliway
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS